Thursday, it was announced by the cricket board of New Zealand that Tim Southee could not join the team on tour to South Africa. A recent report has revealed that he has got himself injured on a thumb and the same is causing him to be ruled out of the tour.
Tim Southee is a fast bowler and the injury is expected to not allow him to go on the field for up to two months. It has been found that when he was diving during a domestic match in the field, he got the thumb wound.
He, 24, had proved himself as New Zealand's most impressive bowler while he played in Sri Lanka during their drawn test series. He was seeking to play in Durban also for Friday's opening Twenty20 game, but physiotherapist Paul Close has told that his ligament is completely ruptured and retracted as he had landed on his thumb during fielding.
It is therefore that he is being left to undergo surgery. NZC medical staff along with a hand specialist has suggested the same. However, a replacement for him for the SA tour is yet to be decided. "He will commence rehabilitation immediately following the procedure, with a view to him returning to cricket during the home summer", Close said.
According to a post published to Microsoft’s official blog on Wednesday, the number of devices running the company’s latest Windows version -- the Windows 10 operating system -- has touched 350 million.
The new milestone in the Windows 10...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
During the course of Thursday proceedings in the ongoing legal scuffle between Google and Oracle...
The Verge has revealed in a Wednesday report, citing a statement released by Lexus, that the working of the head units of a number of vehicles has been affected because of an over-the-air (OTA) update recently rolled out by the company.
...
The drought conditions in California is widening economic split in California. The prospect of...
Tech giant Google posted a video of a developer presentation to the Google Developers YouTube...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
A panel of US medical experts said that there is no...
At the GSMA Mobile World Congress in Shanghai, HTV Vive...
According to a post published to Microsoft’s official...
No matter how dangerous a task it seems to look within a...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).